Clinical Trial Update: The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

View source ↗

Summary

A completed trial evaluating how long NSCLC patients with EGFR mutations benefit from sequential EGFR-TKI therapy (afatinib followed by osimertinib) in uncommon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-squamous, Non-Small Cell Lung Cancer | Status: COMPLETED | Results posted: 2023-05-25